Jeremy Rupon, MD,PhD

Hematology Clinical Program Lead
Pfizer Inc.
Collegeville, Pennsylvania, United States

I am Jeremy Rupon, MD,PhD, Clinical Program Lead for Hematology at Pfizer. I received my undergraduate education at Wake Forest University where I majored in Chemsitry. I received my MD and PhD at the Medical College of Virginia earning my PhD in the laboratory of Dr. Gordon Ginder where we investigated epigentic regulation of silenced globin genes. My internship and residency were completed at the Massachusetts General Hospital for Children. I then completely a fellowship in pediatric hematology and oncology at the Children's Hospital of Philaldephia. I joined Pfizer a few years post-fellowship and have been working on the development of gene therapy for the treatment of hemophilia A and B.

Presentation(s):

• PB0186 - Results from BeneGene-1 Study: Prospective collection of bleeding rate in hemophilia B patients prior to phase 3 study (BeneGene-2) of fidanacogene elaparvovec

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• PB0187 - Impact of One-Stage Clotting Assay Reagents on Factor XIa Levels and Clotting Time with High Activity Factor IX (R338L) Variant

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• OC 52.3 - Efficacy and Safety of Fidanacogene Elaparvovec in Adults with Moderately Severe or Severe Hemophilia B: Results from the Phase 3 BENEGENE-2 Gene Therapy Trial

  Tuesday, June 27, 2023
  11:15 – 11:30 ET